Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04648969 · ClinicalTrials.gov registry record · Phase 2

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

A Phase 2 study, sponsored by Stephanie B. Seminara, MD.

Completed
Registry status
Phase 2
Development phase
18
Enrollment target

NCT04648969: Completed Phase 2 study, sponsored by Stephanie B. Seminara, MD.

NCT04648969 is a Phase 2 study that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04648969, a Phase 2 study, has completed, sponsored by Stephanie B. Seminara, MD.

COMPLETED
Registry status
Phase 2
Development phase
18 participants
Enrollment target

Study Summary

The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.

Primary Outcome

Change in LH amplitude before, during and after kisspeptin administration

Interventions

  • DRUG kisspeptin 112-121
  • DRUG GnRH

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2019-05-03
Est. Completion 2025-08-31
Phase Phase 2
Stephanie B. Seminara, MD

11 total trials

What the finished NCT04648969 record still lists

NCT04648969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).

The record links to 0 conditions, and to 2 interventions - of which kisspeptin 112-121 is the first listed.

NCT04648969 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04648969 about?

NCT04648969 is a clinical study titled "Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism". The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.

What is the current status of trial NCT04648969?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-05-03. Estimated completion is 2025-08-31.

What interventions are being tested in trial NCT04648969?

The interventions under investigation include: kisspeptin 112-121 (DRUG), GnRH (DRUG).

Who is sponsoring clinical trial NCT04648969?

This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04648969's enrollment target sits among peer trials

18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04648969, the US trial registry maintained by the National Library of Medicine. NCT04648969 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.